Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an Acta Neuropathologica study that used a mouse model to show that the alpha-synuclein pathology from ...
This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, ...
HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...
Multiple system atrophy is a rare and fatal neurodegenerative disease, where insoluble inclusions of the protein alpha-synuclein appear in oligodendrocyte cells of the brain. The resulting ...
In a study published in Neuron, researchers have identified four new genetic risk factors for multiple system atrophy (MSA), shedding light on this poorly understood disorder. The study, which ...
Final participant randomized to complete enrollment in Phase 1 clinical trial assessing safety of investigational gene therapy AB-1005 delivered to the putamen in patients with multiple system atrophy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results